Target Price | $16.10 |
Price | $3.06 |
Potential |
426.14%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target Voyager Therapeutics, Inc. 2026 .
The average Voyager Therapeutics, Inc. target price is $16.10.
This is
426.14%
register free of charge
$30.00
880.39%
register free of charge
$9.00
194.12%
register free of charge
|
|
A rating was issued by 12 analysts: 12 Analysts recommend Voyager Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Voyager Therapeutics, Inc. stock has an average upside potential 2026 of
426.14%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 80.00 | 66.14 |
68.00% | 17.32% | |
EBITDA Margin | -98.20% | -160.69% |
294.14% | 63.64% | |
Net Margin | -77.31% | -138.50% |
218.90% | 79.16% |
12 Analysts have issued a sales forecast Voyager Therapeutics, Inc. 2025 . The average Voyager Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Voyager Therapeutics, Inc. EBITDA forecast 2025. The average Voyager Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Voyager Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Voyager Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.13 | -1.67 |
138.05% | 47.79% | |
P/E | negative | |
EV/Sales | negative |
12 Analysts have issued a Voyager Therapeutics, Inc. forecast for earnings per share. The average Voyager Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Voyager Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 27 2025 |
Analyst Rating | Date |
---|---|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 13 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 27 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.